| Blood for DNA analysis | TEXT population (n = 2660) | |
---|---|---|---|
 | No (n = 693) | Yes (n = 1967) |  |
Characteristics at randomization | |||
 White/Caucasian,% | 73 | 92 | 87 |
 Age (years), median (IQR) | 43 (39, 46) | 44 (40, 47) | 43 (40, 46) |
 Normal menstruation, % | 87 | 88 | 87 |
 BMI (kg/m2), median (IQR) | 24 (22, 29) | 24 (21, 28) | 24 (21, 28) |
 Presence of any grade (1–3) hot flashes, % | 5 | 8 | 7 |
 Presence of any grade (1–2) sweating, % | 4 | 7 | 6 |
 Presence of any grade (1–4) musculoskeletal symptoms, % | 13 | 15 | 15 |
Concomitant adjuvant therapy | |||
 Adjuvant chemotherapy, % | 64 | 58 | 59 |
 HER2-directed therapy, % | 3 | 7 | 6 |
Protocol adjuvant therapy | |||
 Treatment assignment |  |  |  |
  Exemestane + OFS, % | 50 | 50 | 50 |
  Tamoxifen + OFS, % | 50 | 50 | 50 |
 Oral endocrine therapy (exemestane or tamoxifen) treatment <12 months, % | 19 | 6 | 10 |
 OFS <12 months, % | 16 | 4 | 7 |
Analysis endpointsa | |||
 Early-onset grade ≥2 hot flashes/sweating, % | 41 | 43 | 43 |
 Early-onset grade ≥2 musculoskeletal symptoms, % | 28 | 26 | 27 |